Results 151 to 160 of about 455,569 (249)

The Role of Baseline Traction and Diabetes Type in Predicting Recurrence After Vitrectomy for Proliferative Diabetic Retinopathy. [PDF]

Clin Ophthalmol
Zhan J, Yang J, Li H, Lu L, Zhao X.
europepmc   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1759-1769, October 2026.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source

Construction and Validation of a Long-Term Visual Prognosis Prediction Model for Proliferative Diabetic Retinopathy After Vitrectomy Based on Machine Learning. [PDF]

Endocrinol Diabetes Metab
Wang X, Shi J, Gao Y, Li T, Han X, Guo L, Jia T, Wang Y.   +7 more
europepmc   +1 more source

Proliferative Diabetic Retinopathy [PDF]

, 2020
openaire   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1726-1734, October 2026.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Determinants of Spousal Loneliness Among Caregivers for Patients with Proliferative Diabetic Retinopathy: A Cross-Sectional Study. [PDF]

J Multidiscip Healthc
Wang T, Cai Z, Wei X, Hu W.
europepmc   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Faricimab for Diabetic Macular Edema in Eyes Vitrectomized for Proliferative Diabetic Retinopathy: A 12-Month Retrospective Study. [PDF]

J Clin Med
Yoon K, Usui-Ouchi A, Sakanishi Y, Ebihara N, Nakao S.   +4 more
europepmc   +1 more source

Relating aqueous to vitreous humor proteomics for identification of reliable biomarkers in proliferative diabetic retinopathy. [PDF]

Sci Rep
Klaassen I, Tanck MWT, Duncan HJ, Yildiz E, Schlingemann RO, Steel DHW.   +5 more
europepmc   +1 more source

Association of the <i>KCNJ11</i> E23K (rs5219) variant with proliferative diabetic retinopathy in Lebanese patients with type 2 diabetes. [PDF]

Front Med (Lausanne)
Nemr R, Echtay A, Kanabekova P, Bauyrzhanova Z, Amanzhol D, Almawi WY.   +5 more
europepmc   +1 more source